Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Pancreatic Neoplasms 3Neoplasms 3Carcinoma, Hepatocellular 3Neoplasm Metastasis 2Glioma 2Glioblastoma 2Solid Tumor 1Camurati-Engelmann Syndrome 1

Interventions

Gemcitabine 205130-nm albumin-bound paclitaxel 84Albumin-Bound Paclitaxel 57pembrolizumab 43Fluorouracil 41Leucovorin 34Oxaliplatin 33Capecitabine 25Nivolumab 22Irinotecan 19Bevacizumab 17Paclitaxel 16Cyclophosphamide 15Cetuximab 15Taxes 13Erlotinib Hydrochloride 13Drug Therapy 13Carboplatin 12irinotecan sucrosofate 11Injections 10Cisplatin 9fludarabine 8ALT-803 8spartalizumab 7olaparib 7avelumab 7Pemetrexed 7Docetaxel 7ruxolitinib 6TH 302 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Pancreatic Neoplasms × LY-2157299 × Clear all
NCT02734160 2019-08-05

A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer

Eli Lilly and Company

Phase 1 Completed
37 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT01373164 2018-05-16

A Study in Metastatic Cancer and Advanced or Metastatic Unresectable Pancreatic Cancer

Eli Lilly and Company

Phase 1/2 Completed
170 enrolled 25 charts
Gastrointestinal

Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms

NCT02154646 2016-02-10

A Study of LY2157299 in Participants With Pancreatic Cancer That is Advanced or Has Spread to Another Part of the Body

Eli Lilly and Company

Phase 1 Completed
6 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡